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OBJECTIVE: Enterobacteriaceae bacteria harboring Klebsiella pneumoniae carbapenemase are a serious worldwide
threat. The molecular identification of these pathogens is not routine in Brazilian hospitals, and a rapid phenotypic
screening test is desirable. This study aims to evaluate the modified Hodge test as a phenotypic screening test for
Klebsiella pneumoniae carbapenemase.
METHOD: From April 2009 to July 2011, all Enterobacteriaceae bacteria that were not susceptible to ertapenem
according to Vitek2 analysis were analyzed with the modified Hodge test. All positive isolates and a random subset
of negative isolates were also assayed for the presence of blaKPC. Isolates that were positive in modified Hodge tests
were sub-classified as true-positives (E. coli touched the ertapenem disk) or inconclusive (distortion of the inhibition
zone of E. coli, but growth did not reach the ertapenem disk). Negative results were defined as samples with no
distortion of the inhibition zone around the ertapenem disk.
RESULTS: Among the 1521 isolates of Enterobacteriaceae bacteria that were not susceptible to ertapenem, 30%
were positive for blaKPC, and 35% were positive according to the modified Hodge test (81% specificity). Under the
proposed sub-classification, true positives showed a 98% agreement with the blaKPC results. The negative predictive
value of the modified Hodge test for detection was 100%. KPC producers showed high antimicrobial resistance
rates, but 90% and 77% of these isolates were susceptible to aminoglycoside and tigecycline, respectively.
CONCLUSION: Standardizing the modified Hodge test interpretation may improve the specificity of KPC detection.
In this study, negative test results ruled out 100% of the isolates harboring Klebsiella pneumoniae carbapenemase-
2. The test may therefore be regarded as a good epidemiological tool.
KEYWORDS: Modified Hodge Test; KPC; Carbapenemase; Ertapenem.
Cury AP, Andreazzi D, Maffucci M, Caiaffa-Junior HH, Rossi F. The modified Hodge test is a useful tool for ruling out klebsiella pneumoniae
carbapenemase. Clinics. 2012;67(12):1427-1431.
Received for publication on August 3, 2012; First review completed on August 24, 2012; Accepted for publication on August 28, 2012
E-mail: anapaulacury@gmail.com
Tel.: 55 11 2661-6136/6348
INTRODUCTION
Carbapenems are one of the last remaining antimicrobial
treatments for multidrug-resistant Enterobacteriaceae, and
resistance to this class of antibiotics is becoming a threat
worldwide (1). Impermeability due to porin loss concomi-
tant with the hyperproduction of cephalosporinases is often
the cause of carbapenem resistance, but serine beta-
lactamases, such as Klebsiella pneumoniae carbapenemase
(KPC), are spreading fast and becoming prevalent world-
wide (1-3). The genes encoding the KPC enzyme are usually
flanked by transposon-related sequences that have been
identified on transferable plasmids, giving these genes the
potential to disseminate to other genera and species (4).
Currently, KPC producers are found all over the world,
with reports from Greece (5), Israel (6), France (7), China (8),
and South America (4).
In Brazil, KPC was first described in the northwestern
region in 2006 and has become an important mechanism of
resistance to carbapenems since then (9-11). In our institu-
tion, carbapenem resistance among Enterobacteriaceae was
only sporadically noted prior to 2005. However, starting in
2008, KPC producers became an epidemiological challenge.
The early recognition of KPC-producing isolates has
become necessary due to the clinical and epidemiological
implications of the presence of KPC. The routine laboratory
detection of KPC is a challenge, especially for laboratories
without molecular diagnostic resources, as is common in
Brazilian hospitals.
The modified Hodge test (MHT) is a phenotypic screen-
ing test for carbapenemases that is used for epidemiological
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purposes, and its use is currently proposed by the Clinical
and Laboratory Standards Institute (CLSI) (12). The MHT is
easy to perform, but divergent specificity values have been
reported, and false-positive results are a concern (13,14).
The aim of this study was to evaluate the performance of
a new proposal for interpreting the modified Hodge test
and detect the blaKPC gene among Enterobacteriaceae isolates,
which were collected in our 2500–bed hospital, that
exhibited ertapenem MICs $1 mg/ml.
MATERIALS AND METHODS
From April 2009 to July 2011, a total of 1521 Enterobacteriaceae
isolates that were not susceptible to ertapenem (ENSEs), with
MICs$1 mg/ml from any clinical specimen, were selected from
among the patient cultures of the Hospital das Clı´nicas da
Faculdade de Medicina da Universidade de Sa˜o Paulo. When
more than one isolate was recovered from a patient, the second
isolate was only included if it was another species or the same
species with a different susceptibility pattern.
Identification and antimicrobial susceptibility testing were
performed using a Vitek2 system (bioMerieux Marcy-L’ile,
France) with the AST-N105 and AST-N104 cards. Categorical
interpretations were performed according to CLSI M100–S21
(12). For colistin, the CLSI breakpoints for P. aeruginosa were the
reference for categorical interpretation, and the U.S. Food and
Drug Administration (FDA) breakpoints were used for
tigecycline. All isolates were tested by the MHT according to
the CLSI recommendations and quality control.
The results of the modified Hodge test were categorized
according to the CLSI recommendations as follows: negative
when there was no distortion of the inhibition zone around
the ertapenem disk, positive when any distortion of the E.
coli ATCC 25922 (strain indicator) inhibition zone was noted
around the ertapenem disk, and indeterminate when the
inhibition of E. coli ATCC 25922 growth around the streak
(tested strain) was evidenced by a clear area.
All isolates with positive modified Hodge test results
were classified using a new sub-classification proposed by
our group: A) a result was considered a true-positive when
E. coli ATCC 25922 touched the ertapenem disk; and B) a
result was considered inconclusive when there was distor-
tion of the E. coli ATCC 25922 inhibition zone around the
ertapenem disk, but the bacteria did not touch the edge of
the disk. See Figure 1 for the modified Hodge test sub-
classification definition in our study.
All isolates with positive and indeterminate modified Hodge
test results were submitted to molecular detection of the blaKPC
gene by PCR. Isolates with negative test results were also
randomly chosen for molecular KPC testing. The primers used
for PCR amplification and the reaction conditions were
described previously (15). The PCR products were visualized
by electrophoresis on 2% agarose gels stained with ethidium
bromide and visualized with UV light.
Two samples of blaKPC amplicons (859 bp) produced by PCR
were selected and submitted to DNA sequencing with a BigDye
Terminator cycle sequencing kit v3.1 (Applied Biosystems Inc.,
Foster City, CA) in an MJ Research PTC-200 DNA Engine
thermal cycler (Bio-Rad Laboratories, Waltham, USA). The
sequencing reaction products were purified by ethanol pre-
cipitation, separated, and analyzed using an ABI Prism 3100
genetic analyzer (ABI, Foster City, USA) following the
manufacturer’s protocols. The sequenced products were
compared using software available at the National Center for
Biotechnology Information website (http://blast.ncbi.nlm.nih.
gov).
The antibiograms for KPC producers and non-producers
were analyzed. The MIC50 and MIC90 values were calcu-
lated using Whonet version 5.4.
The sensitivity, specificity, positive predictive values (PPVs),
and negative predictive values (NPVs) were calculated accord-
ing to the method of Ilstrup (16).
RESULTS
We analyzed 1521 Enterobacteriaceae isolates that were not
susceptible to ertapenem, of which 30% (458) were positive for
blaKPC. Among the blaKPC-positive isolates, 93% were Klebsiella
pneumoniae. The modified Hodge test results are summarized
according to the species distribution and molecular detection of
blaKPC in Table 1. The modified Hodge test was positive in
35.5% of Enterobacteriaceae isolates that were not susceptible to
ertapenem (540), and according to our proposed sub-classifica-
tion, 71% (386) of those isolates showed true-positive results,
and 29% (154) had inconclusive results. The true-positive results
showed 98% agreement with the molecular KPC results,
whereas the level of agreement for the inconclusive results
was only 51%.
The modified Hodge test results according to the sensitivity,
specificity and predictive values for KPC detection are shown in
Table 2. The modified Hodge test had a 100% negative
predictive value.
Specimens yielding KPC-producing isolates were primar-
ily urine samples (37%), rectal swabs (17%), blood samples
(10%), and catheters (10%).
The antimicrobial susceptibility profile of the KPC-producing
isolates revealed high resistance rates to all cephalosporins,
aztreonam (98.9%), piperacillin/tazobactam (99.3%), and
fluoroquinolones (92%). Amikacin and gentamycin had
susceptibility rates of 95% and 88%, respectively. Tigecycline
had an 8% susceptibility rate, and colistin had an MIC50 of
2 mg/l and MIC90 of 4 mg/l. The meropenem results for KPC
isolates from the automated system indicated that 50% were
resistant, but the disk method indicated that 70% of isolates
were resistant (data not shown). The KPC non-producing
isolates also had high rates of resistance to all cephalosporins,
aztreonam, piperacillin/tazobactam, and fluoroquinolones, and
the detailed information is summarized in Table 3.
The DNA sequencing of the KPC-producing isolates
confirmed that they carried the KPC-2 variant.
Figure 1 - Modified Hodge test (MHT) with ertapenem disks.
Interpretation of the MHT results proposed in this study: A) true-
positive MHT, B) inconclusive MHT and C) negative MHT.
Modified Hodge test for KPC detection.
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DISCUSSION
The presence of blaKPC deserves special attention because
isolates harboring this plasmid gene are usually multidrug
resistant, limiting the therapeutic options available and
causing a high mortality rate (17).
KPC represents an epidemiological challenge for infection
control groups because it can spread very quickly, and there
are limited treatment options available (18). The early
detection of such isolates is critical. Screening for KPC
producers by identifying Enterobacteriaceae isolates that are
not susceptible to ertapenem has a low specificity but is a
starting point to identify isolates harboring carbapenemases.
The modified Hodge test is relatively easy to perform in
standard microbiology laboratories, and the standardization
of the interpretation of the results may improve the
specificity of this test for KPC detection.
Infections caused by KPC-producing isolates are now a
concern in our institution, and 30% of the Enterobacteriaceae
isolates that were not susceptible to ertapenem were KPC
positive in this study period. The majority of those isolates
(37%) were from urine cultures, but the positivity rate for
KPC among blood isolates was proportionally higher (data
not shown).
The molecular detection of blaKPC is the gold standard for
diagnosis, but the majority of standard laboratories in our
country do not have the resources necessary to perform this
test on a routine basis. Phenotypic tests should be made
available to detect KPC early or rule it out. The modified
Hodge test may detect the presence of carbapenemases, but
it is not specific for KPC and may have false-positive results
due to non-carbapenemase enzymes, such as AmpC and/or
extended-spectrum beta-lactamases (ESBLs), combined with
Table 1 - Distribution of 1521 Enterobacteriaceae isolates that were not susceptible to ertapenem (ENSE) according to
the modified Hodge test (MHT) results and the presence of blaKPC.
MHT resultsa
N˚ ENSE Organism
N˚ ENSE
(blaKPC tested)
blaKPC
Negative
blaKPC
Positive
K. pneumoniae 481 (191) 191 0
E. cloacae 293 (111) 111 0
E. aerogenes 85 (16) 16 0
E. coli 62 (22) 22 0
S. marcescens 15 (8) 8 0
Negative P. mirabilis 12 (1) 1 0
975 (64.1%) M. morgannii 8 (0) 0 0
C. freundii 7 (4) 4 0
E. gergoviae 7 (2) 2 0
K. oxytoca 2 (0) 0 0
P. stuartii 2 (0) 0 0
P. vulgaris 1 (0) 0 0
Total 975 (355) 355 (100%) 0 (0)
True-positiveb K. pneumoniae (354) 1 353
386 (71%) E. cloacae (10) 3 7
E. aerogenes (3) 0 3
E. coli (6) 0 6
S. marcescens (6) 3 3
C. koseri (1) 0 1
Positive C. freundii (1) 0 1
540 (35.5%) E. asburiae (2) 0 2
K. oxytoca (2) 0 2
Total (386) 7 (2%) 379 (98%)
Inconclusiveb K. pneumoniae (111) 40 71
154 (29%) E. cloacae (26) 24 2
E. aerogenes (10) 10 0
E. coli (2) 0 2
E. gergoviae (2) 2 0
E. asburiae (1) 0 1
S. marcescens (2) 0 2
Total (154) 76 (49%) 78 (51%)
Indeterminate E. cloacae (4) 3 1
6 (0.4%) E. coli (1) 1 0
K. pneumoniae (1) 1 0
Total (6) 5 (86%) 1 (14%)
Total: 1521 (901) 443 458
aPositive, indeterminate, and negative results were defined according to the recommendations of the Clinical and Laboratory Standards Institute.
bTrue-positive and inconclusive results were defined according to this study’s proposal (see Figure 1).
Table 2 - Performance of the modified Hodge test (MHT)
for KPC detection.
MHT
N˚
Isolates
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
True-positive 386 100 98 98 100
Inconclusive 154 100 82 51 100
Positivea 540 100 81 85 100
aTrue-positive plus inconclusive results.
PPV - positive predictive value, NPV – negative predictive value.
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porin loss. Positive results could also be due to other
carbapenemases. In the literature, the specificity of the
modified Hodge test differs because some authors analyzed
data for distinct bacteria groups, such as non-fermenters
and Enterobacteriaceae, and detected different carbapene-
mases, such as NDM (13). In our study, the modified Hodge
test was evaluated only for Enterobacteriaceae bacteria and
KPC producers, which may explain the high level of
agreement with the molecular results.
The proposed positive modified Hodge test category had
98% agreement with the molecular blaKPC results, high-
lighting the good positive predictive value of KPC detection
among Enterobacteriaceae when a standardized method for
interpretation is in place. Seven isolates showed true-
positive results and were negative for blaKPC, but an
accurate analysis of the reason for these discrepancies was
limited because no tests were performed for other carbape-
nemases. Of the isolates in the inconclusive group, 49%
were negative for blaKPC, and these negative strains most
likely produced CTX-M or hyperproduced AmpC in
association with porin loss. Another possibility is that these
isolates produced carbapenemases other than KPC.
The indeterminate result, as proposed by the CLSI, does
not have a clear microbiological or clinical interpretation in
the literature and should be the focus of future studies.
Enterobacteriaceae bacteria that not susceptible to ertape-
nem but have a negative modified Hodge test result are not
KPC producers.
Although tests other than the modified Hodge test, such
as the aminophenylboronic acid and dipicolinic acid tests,
may also be options for the phenotypic screening for
carbapenemases (19), the supplies necessary for these tests
are not routinely available in the majority of Brazilian
laboratories.
The antibiograms of the 458 KPC isolates generated using the
automated system revealed multidrug resistance and showed
that 43% of isolates were susceptible to meropenem (MIC
#1 mg/ml). The meropenem susceptibility rates were not
reproducible by TREK microdilution panels (Cleveland, OH)
or the disk diffusion method (OXOID) (data not shown), with
45% very major errors (VMEs) for this drug. Corroborating
these findings, the literature contains reports of unacceptable
VME levels for meropenem when KPC isolates were tested
using automated systems. Microbiologists and clinicians should
be aware of the current problems regarding false susceptibility
results for meropenem among KPC isolates when only
automated systems are used to screen isolates (20). Regarding
the colistin and tigecycline Vitek results, our internal validation
process did not show major discrepancies with the E-test (data
not shown), and published studies have not reported major
problems with these drugs (21). Every laboratory should
perform its own validation of automated systems when CLSI
breakpoints are in place.
The modified Hodge test results for Enterobacteriaceae
using standardized readings are a useful phenotypic and
epidemiological tool to identify KPC isolates while waiting
for molecular results. Negative modified Hodge test results
ruled out all KPC isolates in our institution in an efficient
and timely manner.
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